CSL Behring Submits FDA Approval for Long Acting Hemophilia B Product

December 16, 2014

CSL Behring announced on Tuesday, December 16, 2014 that it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Once approved by the FDA, rIX-FP (Coagulation Factor IX {Recombinant}, Albumin […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.